呋喃唑酮联合保肝药物治疗慢性酒依赖对照研究

A control study of furazolidone plus liver-protective drugs in chronic alcohol dependence

目的探讨呋喃唑酮联合保肝药物治疗慢性酒依赖的临床疗效和安全性。方法将100例慢性酒依赖患者随机分为两组各50例，两组均口服呋喃唑酮治疗及支持对症治疗，实验组联合保肝治疗。观察30d。比较两组治疗后躯体反应及戒断反应消失时间，肝功能状况及随访1a末戒酒状况。结果治疗后实验组胸闷、心慌发生率显著低于对照组（P〈0．01），戒断反应消失时间显著早于对照组（t=13．403，P〈0．01）；肝功恢复正常率显著高于对照组（χ2=4．441，P〈0．05）。随访1a末两组复饮率均较低。结论呋喃唑酮联合保肝药物治疗慢性酒依赖患者疗效显著，安全性高。

Objective To explore the clinical efficacy and safety of furazolidone plus liver-protective drugs in chronic alcohol dependence. Methods One hundred patients with chronic alcohol dependence were randomly divided into two groups of 50 patients each, both groups took orally furazolidone and received sup- portive symptomatic treatment, and the experimental group was plus liver-protective therapy for 30 days. Post-treatment somato-response, abstinence reaction extinction time, liver function and alcohol withdrawal at the end of 1-year follow-up were compared. Results After treatment, incidences of dyspnea and palpita- tion were significantly lower （P〈0. 01）, abstinence reaction extinction time significantly earlier （t = 13. 403, P〈0.01）, and the recover ratio of liver function significantly higher （χ2=4. 441,P〈0.05） in the experimental than in the control group. Re-drinking rates of both groups were lower. Conclusion Furazolidone plus liver-protective drugs have an evident effect and higher safety in chronic alcohol dependence.